BD (Becton, Dickinson and Company) (NYSE: BDX) announced the completion of patient enrollment in its PREVENT clinical trial, which is evaluating Phasix™ Mesh for the prevention of incisional hernias following abdominal surgery.

The trial enrolled 477 patients across 32 sites in the United States and Europe. According to the company, the study is the first large-scale randomized trial evaluating prophylactic reinforcement for incisional hernia prevention using a resorbable mesh. No products are currently approved for this indication.

The trial focuses on patients at high risk of developing a hernia following elective open midline abdominal surgery. Patients will be monitored through a primary endpoint at 24 months, with follow-up planned for up to five years to assess safety and clinical outcomes.

BD said it plans to submit data from the study to the U.S. Food and Drug Administration as part of a regulatory pathway for the indication, following completion of the primary endpoint assessments.

"By evaluating Phasix™ Mesh in hernia prevention, we are building on decades of innovation in abdominal wall surgery and generating evidence that could help broaden the role of regenerative technologies for patients at risk of post-surgical complications," said Rian Seger, worldwide president of Surgery at BD.

The information is based on a press release issued by BD.